Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
3.220
-0.050 (-1.53%)
At close: May 13, 2025, 4:00 PM
3.260
+0.040 (1.24%)
Pre-market: May 14, 2025, 8:41 AM EDT
Company Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.
The company’s lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids.
The company is headquartered in New York, New York.
Protara Therapeutics, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Jesse Shefferman |
Contact Details
Address: 345 Park Avenue South, 3rd Floor New York, New York 10010 United States | |
| Phone | 646 844 0337 |
| Website | protaratx.com |
Stock Details
| Ticker Symbol | TARA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001359931 |
| CUSIP Number | 74365U107 |
| ISIN Number | US74365U1079 |
| Employer ID | 20-4580525 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jesse Shefferman | Co-founder, Chief Executive Officer, President and Director |
| Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. | Co-Founder and Chief Scientific Operations Officer |
| Patrick Fabbio M.B.A. | Chief Financial Officer |
| Hannah Fry | Vice President, Principal Accounting Officer and Controller |
| Justine O'Malley | Senior Vice President of Investor Relations and Corporate Affairs |
| Mary J. Grendell J.D. | General Counsel and Corporate Secretary |
| Dr. Shane Williams Ph.D. | Chief People Officer |
| Dr. Leonardo Viana Nicacio M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| May 8, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| Apr 28, 2025 | SCHEDULE 13G/A | Filing |
| Apr 28, 2025 | 424B7 | Filing |
| Apr 28, 2025 | 8-K | Current Report |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 26, 2025 | 144 | Filing |